Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
NCT ID: NCT05315856
Last Updated: 2022-04-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2021-03-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses
NCT06824779
Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population
NCT06763887
Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines
NCT05970887
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
NCT06091410
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ChAdOx1 vaccine group
AstraZeneca vaccine (chimpanzee adenovirus-vectored vaccine, 0.5 mL \[5 × 1010 viral particles\] per dose)
either BNT162b2 or ChAdOx1 vaccine
Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
BNT162b2 vaccine group
Pfizer-BioNTech vaccine (mRNA vaccine; 0.3 mL \[30 μg\] per dose)
either BNT162b2 or ChAdOx1 vaccine
Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
either BNT162b2 or ChAdOx1 vaccine
Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy adults without underlying medical condition
Exclusion Criteria
19 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ajou University School of Medicine
OTHER
Hallym University Kangnam Sacred Heart Hospital
OTHER
Korean Center for Disease Control and Prevention
OTHER_GOV
Korea University Guro Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joon Young Song
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joon Young Song, MD
Role: STUDY_CHAIR
Korea University Guro Hospital
Jung Yeon Heo, MD
Role: PRINCIPAL_INVESTIGATOR
Ajou University School of Medicine
Yu Bin Seo, MD
Role: PRINCIPAL_INVESTIGATOR
Hallym University Kangnam Sacred Heart Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ajou University School of Medicine
Suwon, Gyeonggi-do, South Korea
Kangnam Sacred Heart Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yu Bin Seo
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021GR0099
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.